Tag: utility

Former brewery turned apartment community to undergo historic rehabilitation, preserving affordability and enhancing resident experience

BOCA RATON, FL, June 10, 2025 (GLOBE NEWSWIRE) -- DeFi Development Corp. (Nasdaq: DFDV) (the “Company” or “DeFi Dev Corp.”), the first US public company with a treasury strategy built to accumulate and compound Solana (“SOL”), today announced a strategic partnership with Exponent, a leading Solana-native yield strategy platform. This collaboration will see dfdvSOL, a liquid staking token (LST) adopted by DeFi Dev Corp., integrated into Exponent’s innovative fixed-yield and leverage yield farming vaults.

With this integration, Exponent users can deploy dfdvSOL across three key yield strategies, each tailored to different risk and return preferences:

Battery energy storage system will provide critical and reliable energy to the ERCOT power grid

MESQUITE, NV, June 10, 2025 (GLOBE NEWSWIRE) -- Dogecoin Cash Inc. (OTCQB: CBDS), a publicly traded company operating at the intersection of digital assets and public equity markets, announced today that it has received approval to change its stock ticker symbol to DOGP, effective June 10, 2025. The new symbol better aligns with the company’s identity, mission, and growing role in the decentralized meme economy.

“This move marks our territory in the memeosphere,” said David Tobias, CEO of Dogecoin Cash Inc. “DOGP isn’t just a ticker — it’s a signal that we’re serious about building in the crypto culture and our commitment to real innovation with real compliance. It signals that we’re not only part of the conversation — we’re leading the barkstorm.”

BENGALURU, India, June 09, 2025 (GLOBE NEWSWIRE) -- RenaissThera Private Limited (“RenaissThera”), a Bengaluru-based biotechnology company, announced a major milestone in its obesity drug discovery program targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR). GIPR, an incretin receptor, is a validated target for peptide-based parenteral therapies where both stimulation and inhibition has shown efficacy in treating obesity and its co-morbidities. RenaissThera is developing novel, oral small molecules, both agonists and antagonists, as a more affordable and convenient alternative aiming to expand access for underserved populations in the global obesity market projected to reach USD 38 billion by 2032. Oral small molecules are more economical to manufacture and distribute than peptide-based obesity drugs. These molecules were designed and screened using proprietary AI and ML based platforms, followed by demonstrating in-vitro activity in cell lines and in-vivo activity to impact GIPR in mice to yield “Hits”. RenaissThera now is advancing these Hits to the Lead optimization program to select candidates for pre-IND studies.

NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Ibotta, Inc. (NYSE:IBTA), NET Power, Inc. (NYSE:NPWR), Zenas BioPharma, Inc. (NASDAQ:ZBIO), and Avis Budget Group, Inc. (NASDAQ:CAR). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.